Theratechnologies Revises Fiscal Revenue Target Amid Continuity Concerns

Theratechnologies Adjusts Fiscal Revenue Target Amid Financial Challenges

Theratechnologies, a biotechnology firm, has revised its fiscal revenue target to a range of $82-$85 million following a previous adjustment made in mid-July. This update comes after the company reported a reduced loss of $746,000 for the third quarter, with revenues totaling $20.9 million for the period.

In response to ongoing financial concerns, Theratechnologies is actively seeking support from lenders, requesting a waiver for liquidity breaches and implementing strict expense management under its revised 2022 credit agreement. The company has also indicated that an equity issue may be necessary if these plans do not come to fruition.

As part of its strategic initiatives, Theratechnologies has submitted a new concentrated "F8" formulation of tesamorelin for review. This formulation aims to reduce the administration volume needed for treating HIV-related lipodystrophy, potentially offering a more efficient treatment option for patients. The submission underscores the company’s dedication to innovation and patient care, even amidst its current financial hurdles.

This article was generated with the assistance of AI and reviewed by an editor.